On Thursday, in the course of current trade, Shares of Transocean Ltd. (NYSE:RIG), gained 4.21%, and is now trading at $20.07.
Transocean, declared that it has reached two separate settlement agreements, with the Plaintiffs` Steering Committee (the “PSC”) and with BP Exploration & Production Inc. and BP America Production Co. (“BP”). These settlements together resolve substantially all outstanding claims against Transocean arising from the April 20, 2010, Macondo Well incident involving the Deepwater Horizon in the Gulf of Mexico.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services. As of February 17, 2015, it owned or had partial ownership interests in, and operated 71 mobile offshore drilling units that comprise of 44 high-specification floaters, 17 midwater floaters, and 10 high-specification jackups.
During an Afternoon trade, Shares of Kite Pharma, Inc. (NASDAQ:KITE), dipped -0.31%, and is now trading at $51.83.
On May 15, Kite Pharma stated financial results for the quarter ended March 31, 2015.
“We’re very happy with our accomplishments this year, which have significantly expanded our platform for discovering and advancing both chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. “We’ve reached a broadly enabling CAR partnershipwith Amgen and attained new TCR assets with the acquisition of TCF(TM) in the Netherlands. Further, we are excited to have secured new facilities for clinical and commercial manufacturing, and we have expanded our leadership team with key hires.”
Dr. Belldegrun continued, “We have built the foundation which we believe will enable us to continue delivering on our plan to advance KTE-C19 into development and continue to expand our product pipeline. We also have a poster presentation at the forthcoming 2015 American Society of Clinical Oncology annual meeting, and we are excited to declare our first Investor Day that will take place on June 23rd in New York, for which we will convene key thought leaders and also plan to webcast the event.”
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Shares of Regions Financial Corporation (NYSE:RF), during its Thursday’s current trading session gained 0.29%, and is now trading at $10.29.
Regions Bank declared that Nikki Stock Beem, a mortgage loan originator in Frankfort, Indiana, is the May 2015 recipient of the Regions Bank Better Life Award. The Better Life Award is the top honor given to a Regions associate for outstanding dedication and job performance, in addition to exemplary involvement and commitment to the community.
In addition to the recognition, Regions donates $1,000 in the name of the recipient to a nonprofit organization of the winner’s choice. Beem chose the Boys and Girls Club of Clinton County, where she serves as a mentor. A video of Beem is accessible on the Regions Financial YouTube channel.
Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, in addition to equipment lease financing services.
Finally, Splunk, Inc. (NASDAQ:SPLK), gained 1.81% Thursday.
Splunk, declared that Surescripts, the nation’s largest health information network, has standardized on Splunk® software for information security and risk administration to continue its crackdown on healthcare fraud. Splunk Enterprise empowers Surescripts to sift through billions of annual electronic prescriptions and other health data transactions among doctors, pharmacies and health plans, and analyze the data to assist uncover fraudulent activity. To learn more, read the Surescripts case study on the Splunk website.
Fraud investigations can take months or years to complete, but Splunk Enterprise assists many organizations detect fraud much faster. Citing a need for faster and deeper analysis, Surescripts replaced its legacy SIEM solution with Splunk Enterprise to gain a real-time understanding of breaches and to assist with incident investigations. For instance, Surescripts has an automatic alert for whenever a doctor self-prescribes a medication, so its fraud teams can investigate. Surescripts also uses Splunk dashboards to track core data like state, drug, age and prescriber to easily identify spikes in velocity or geographic hot spots. Multiple teams across the organization are using Splunk Enterprise, counting the security, IT, server, network, database and development teams.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The companys products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
